Clinuvel To Build Vitiligo Pipeline And Commercial Presence
This article was originally published in The Pink Sheet Daily
Executive Summary
Following EU approval last year of its lead sunlight-intolerance product Scenesse, the rare dermatological disease biotech has turned to developing its vitiligo pipeline.
You may also be interested in...
Aurinia Closing In On Lupus Nephritis With Voclosporin
Canada’s Aurinia Pharmaceuticals expects to file a US NDA in the first half of next year on the use of its next-generation calcineurin inhibitor, voclosporin, in lupus nephritis, a condition with no approved therapies.
Mixed Early Phase III Results With Aldeyra’s First-In-Class Dry Eye Candidate
The first part of Aldeyra’s Phase III RENEW study of the aldehyde trap candidate, reproxalap, shows positive effects on one of two co-primary endpoints and indicates an induction-maintenance dosing regimen should be used in part 2 of the study, expected to start in the first half of next year.
Pipeline Watch: Phase III Readout For Avacopan, Phase III Start For Vutrisiran
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: